Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma

Due to the CD1d restricted recognition of altered glycolipids, V24-invariant natural killer T (iNKT) cells are excellent tools for cancer immunotherapy with a significantly reduced risk for graft-versus-host disease when applied as off-the shelf-therapeutics across Human Leukocyte Antigen (HLA) barr...

Full description

Bibliographic Details
Main Authors: Renée Poels, Esther Drent, Roeland Lameris, Afroditi Katsarou, Maria Themeli, Hans J. van der Vliet, Tanja D. de Gruijl, Niels W.C.J. van de Donk, Tuna Mutis
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:International Journal of Molecular Sciences
Subjects:
CAR iNKT
multiple myeloma
CD38
BCMA
adoptive immunotherapy
chimeric antigen receptor
Online Access:https://www.mdpi.com/1422-0067/22/3/1096

Internet

https://www.mdpi.com/1422-0067/22/3/1096

Similar Items